Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma

Kidney Cancer Clinical Trial

Official title:

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Temsirolimus, After 1st Line Anti-VEGF Treatment in Patients With Advanced Renal Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01264341
• Other study ID #: HE 21/10
• Secondary ID: 2010-020664-38
• Status: Terminated
• Phase: Phase 2
• First received: December 20, 2010
• Last updated: February 13, 2017
• Start date: December 2010
• Est. completion date: July 2015

Study information

• Verified date: February 2017
• Source: Hellenic Cooperative Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the combination of bevacizumab/temsirolimus is effective in patients with advanced renal carcinoma progressing after anti-VEGF treatment

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 39
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients (18th year of age completed)

• Signed and dated written informed consent form prior to any procedures related to this protocol.

• Histologically confirmed advanced clear cell renal cancer.

• Measurable disease.

• Failure of first line anti-VEGF treatment.

• Performance status 0-2, according to Eastern Cooperative Oncology Group (ECOG) .

• Satisfactory hematological parameters:

• White blood cell count > 4000 mm3.

• Platelet count 100000/mm3.

• Neutrophil blood cell count > 1200/ mm3 .

• Hemoglobin > 9,0 g/dL (can be achieved with red blood cell transfusion).

• Satisfactory biochemical parameters:

• Serum creatinine < 2 x Upper Limit of Normal(ULN)

• Aspartate Aminotransferase (AST)<2,5 x ULN

• Alanine Transaminase (ALT)< 2,5 x ULN.

• Bilirubin <2 x ULN

• (For female patients) Absence of pregnancy (negative pregnancy test for women of reproductive age before enrollment).

• (For female patients) Non-lactating women.

• Use of efficient contraceptive measures (women and men) to prevent possible pregnancy of female patient or female partner of a male patient during treatment and until 6 months after the end of treatment.

Exclusion Criteria:

• Prior treatment with mTOR inhibitor.

• Major surgery (including open biopsy) or insufficient recovery or existence of major trauma within 4 weeks before enrollment.

• Uncontrolled hypertension.

• Active infection requiring systemic treatment within 4 weeks prior to enrollment.

• Minor surgery (for instance, catheter placement) within 2 days before enrollment.

• Scheduled major surgery within the treatment period.

• Medical history in the last 6 months prior to enrollment of significant cardiovascular disease, diabetes, cardiac infarction, unstable angina, uncontrolled arrhythmia or significant heart failure.

• Indications of uncontrolled metastases or disease progression in CNS lesions (the suspicion of uncontrolled metastases or disease progression should be eliminated by imaging techniques within 14 days prior to enrollment).

• Medical history in the last 5 years prior to enrollment of any other malignancies (excluding the basal or squamous skin cell carcinoma or in situ carcinoma of the cervix).

• History of non-healing wound including active gastric ulcer.

• History of fistula in the last 6 months prior to enrollment.

• History of gastrointestinal perforations.

• Patient incapacity (for psychiatric or social reasons) to conform with the protocol.

• History of hemorrhagic predisposition.

• History of hypersensitivity to the medications under investigation.

• Significant proteinurea.

• Prior immunotherapy within 4 weeks prior to enrollment.

• Prior radiation treatment within 2 weeks prior to enrollment.

• Concomitant medication with inducers or strong inhibitors of the coenzyme CYP3A4 (see Appendix 5 for an indicative list of active compounds).

• Concurrent participation in other interventional clinical trials with investigational medicinal products.

• History of chronic interstitial lung disease.

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Kidney Cancer
• Kidney Neoplasms

Intervention

Drug:
• Bevacizumab
Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal.
• Temsirolimus
Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal.

Locations

Country	Name	City	State
Greece	Agii Anargiri Cancer Hospital, 2nd Dept of Medical Oncology	Athens
Greece	Agii Anargiri Cancer Hospital, 3rd Dept of Medical Oncology	Athens
Greece	General Hospital of Athens "Hippokratio"	Athens
Greece	General Peripheral Hospital of Athens "Alexandra"	Athens
Greece	Metropolitan Hospital, 1st Dept of Medical Oncology	Athens
Greece	Metropolitan Hospital, 2nd Dept of Medical Oncology	Athens
Greece	University Hospital of Patras	Rio, Patras
Greece	Papageorgiou General Hospital	Thessaloniki

Sponsors (1)

Lead Sponsor	Collaborator
Hellenic Cooperative Oncology Group

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	6-month Progression Free Survival (PFS)	Proportion of patients who are progression-free at 6month evaluation from treatment initiation	32 months
Secondary	Progression Free Survival (PFS)	PFS will be calculated from date of treatment initiation until disease progression or death (whichever occurs first)	Tumor assessments will be performed every 8 weeks during treatment and at discontinuation, unless it was performed within the last 4 weeks
Secondary	Overall Survival (OS)	OS will be calculated from the date of treatment initiation to the date of death or last contact	48 months
Secondary	Response Rate (RR)	RR is defined as the overall percentage of patients with partial (PR) or complete response (CR). The evaluation of responses will be performed according to RECIST criteria	Tumor assessments will be performed every 8 weeks during treatment and at discontinuation, unless it was performed within the last 4 weeks
Secondary	Tumor Shrinkage	Tumor shrinkage will be computed using waterfall plots	Tumor assessments will be performed every 8 weeks during treatment and at discontinuation, unless it was performed within the last 4 weeks
Secondary	Adverse Events (AEs) of all participants will be recorded and assessed upon signature of the informed consent form, until 30 days after the last administration of study treatment.	Adverse Events will be graded according to the NCI CTCAE v3.0 criteria and will be reported in a frequency table according to the highest severity grade observed per patient	3 years
Secondary	Quality of Life (QoL) assessment	QoL will be assessed using the EORTC QLQ C-30 questionnaire. The change in the QoL during treatment will be estimated using the Wilcoxon paired t-test	At baseline and every 8 weeks during treatment
Secondary	Investigation of antiangiogenic factors (FGF, VEGF, VEGFRR)	Changes in serum levels of antiangiogenic factors during treatment and correlation to the outcome of study treatment.	36 months